Celyad to Begin Phase 1 Trial of Donor-derived CAR T-cell Therapy for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
First Patient Dosed in Trial Testing Belantamab Mafodotin, Nirogacestat Combo in RRMM Patients
A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s…
EU Approval Urged for GSX’s Belantamab Mafodotin for Heavily Treated Myeloma
GlaxoSmithKline’s investigational therapy belantamab mafodotin has been…
$1.9M Grant Awarded for Study on How Fat Cells Help Myeloma Cells Resist Treatment
A new research project aiming to better understand how…
Sarclisa Triple Combo Prolongs Life Without Disease Progression in Some Myeloma Patients, Interim Data Show
A combination of Sarclisa (isatuximab) plus standard…
FDA Office Favors Antibody-drug Conjugate for Advanced Multiple Myeloma
An office of the U.S. Food and Drug Administration…
